Unit 1 Flashcards

1
Q

characteristics of normal cells

A
  • apoptosis
  • specialized
  • no invasion
  • no evasion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

characteristics of cancer cells

A
  • no apoptosis
  • invasion
  • less specialized
  • evasion
  • angiogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

neoplasia

A

abnormal cell growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

neoplasm

A
  • cluster of abnormal cells
  • tumor, mass
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

malignant

A
  • harmful
  • cancerous
  • invasive
  • metastasizing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

benign

A
  • no metastasis
  • no invasion
  • noncancerous
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

oncogenesis

A

tumor formation and development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

carcinogenesis

A
  • normal cells → cancer cells
  • often d/t chemical, viral, or radioactive damage to genes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

angiogenesis

A

formation of new blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hyperplasia

A
  • ↑ normal cells in organ or tissue
  • may or may not become cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

dysplasia

A
  • abnormal, noncancerous cells
  • may or may not become cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

cancer types

A
  • carcinoma
  • adenocarcinoma
  • sarcoma
  • leukemia
  • lymphoma
  • myeloma
  • melanoma
  • brain and spinal cord
  • germ cell
  • neuroendocrine
  • carcinoid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

carcinoma origin

A

epithelial tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

adenocarcinoma origin

A
  • glandular tissues/organs
  • examples
    • lung
    • prostate
    • pancreatic
    • esophageal
    • endometrial
    • colorectal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

types of carcinomas

A
  • adenocarcinomas (glandular origin)
  • basal cell
  • squamous cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sarcoma origin

A
  • mesenchymal (connective) tissue
    • bone
    • adipose
    • tendons
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

leukemia origin

A

blood-forming cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

lymphoma origin

A

lymph tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

myeloma origin

A

plasma cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

melanoma origin

A

skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

plasma cells

A

type of WBC that secretes ↑ antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

germ cell tumor origin

A

ovaries, testes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

carcinoid tumor origin

A
  • neuroendocrine cells of
    • intestinal tract
    • bile ducts
    • pancreas
    • bronchus
    • ovary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

neuroendocrine tumor origin

A

cells of endocrine and nervous systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
cancer risk factors
* age * ETOH * carcinogen exposure * chronic inflammation * diet * hormones * immunosuppression * infections * obesity * radiation * sunlight * tobacco
26
diet changes to ↓ CA risk
* ↓ animal fats, nitrites, red meat * ↑ * bran, cruciferous vegetables * vitamins A and C * limit ETOH: 1-2 drinks/day * breastfeed exclusively for ≥ 6 mo
27
behavior modifications to ↓ CA risk
* no smoking * limit * sun exposure * sexual partners * avoid * known carcinogens * tanning beds * sharing needles * unprotected sex
28
at-risk tissues to remove to ↓ CA risk
* moles * colon polyps * uterine polyps
29
chemoprevention
drugs, chemicals, nutrients to reverse gene damage
30
ASA + celecoxib ↓ risk for ...
colon cancer
31
vitamin D + tamoxifen ↓ risk of ...
breast cancer
32
lycopene ↓ risk of ...
prostate cancer
33
only vaccine for CA prevention
HPV
34
benefit of CA screening and early detection
↓ deaths
35
Cancer screening changes with _____ and differs among \_\_\_\_\_.
* with **evidence** * differs among **experts**
36
breast CA screening
* clinical breast exam * mammogram
37
colorectal CA screening
* fecal occult blood test * colonoscopy
38
prostate CA screening
DRE
39
cervical cancer screening
Pap smear
40
**7 warning signs of cancer (CAUTION)**
* change in bowel or bladder habits * a sore that doesn't heal * unusual bleeding or discharge * thickening or lump in breast or elsewhere * indigestion or dysphagia * obvious changes in warts or moles * nagging cough or hoarseness
41
PSA
prostate specific antigen
42
imaging for CA Dx and follow-up
* X-ray * CT * MRI * PET * PET-CT * SPECT
43
DRE
* digital rectal exam * screening for prostate cancer
44
shave Bx
* for basal or squamous cell skin CAs * removes shallow layer of skin
45
punch Bx
* for deeper skin lesions * removes tissue with hollow, round cutting tool
46
bone marrow Bx/aspiration
for leukemias
47
endoscopic Bx
for joints, respiratory system, body cavities, hollow organs
48
bronchoscopy
scope of respiratory system
49
arthroscopy
scope of joints
50
mediastinoscopy
scope into mediastinum
51
thoracoscopy
scope into thoracic cavity
52
enteroscopy
scope of small intestine
53
sigmoidoscopy
scope of sigmoid colon
54
endoscopy
scope of GI tract
55
needle Bx
* for many soft-tissue tumors and skin * types * fine needle aspiration * core needle aspiration: takes larger sample, some tissue
56
open Bx
* surgical Bx * types * incisional removes part * excisional removes all
57
sentinel lymph node Bx
* removal of nodes near tumor to look for metastasis * dye used to map lymph nodes fed by tumor * sentinel node studied * negative → others assumed negative * positive → dissection * [video](https://www.mayoclinic.org/tests-procedures/sentinel-node-biopsy/multimedia/sentinel-node-biopsy/vid-20084727)
58
sentinel lymph node
first node fed by tumor
59
lymph node dissection
suspect lymph nodes removed, and sample viewed under microscope
60
RN responsibilities before Bx
* answer questions * ensure signed consent * NPO * baseline VS * labs as ordered * PT * Plt * renal fxn
61
RN duties during Bx
* instruct pt on positioning * talk pt through process * meds as ordered for * moderate sedation * pain * anxiety * monitor VS
62
RN responsibilities after Bx
* post-op recovery * monitor * for bleeding * wound closure/dressing * teach * wound care * activity restrictions * when, why to follow up * urgent, emergent S/Sx
63
cancer grading
GX-G4
64
GX
grade cannot be determined
65
G1
* cells well-differentiated * malignant, but slow-growing
66
G2
* intermediate * moderately differentiated * more malignant characteristics
67
G3
* high * poorly differentiated * few normal cell characteristics
68
G4
* high * poorly differentiated * determining origin is difficult or impossible
69
high-grade tumors labels
G3-G4
70
intermediate tumor label
G2
71
low-grade tumor label
G1
72
cancer stage
* extent of growth and spread * tumor size * spread to lymph nodes, other tissues
73
purpose of cancer staging
* understanding severity and chance of survival * Tx planning * ID of appropriate clinical trials
74
Cancer is referred to by stage at \_\_\_\_\_, regardless of later _____ or \_\_\_\_\_.
* stage at **diagnosis** * regardless of **metastasis** or **growth**
75
TNM
* commonly used cancer staging system * stands for * tumor size and extent * nearby lymph node involvement * metastasis
76
TNM staging system components
* TX-T4 * NX-N3 * MX-M1
77
TX-T4 interpretation
* TX: cannot be measured * T0: cannot be found * T1-T4: size/extent of tumor ↑ with number
78
TNM lymph node interpretation
* NX: cannot be measured * N0: no CA in nearby lymph nodes * N1-N3: number/site of lymph nodes w/ CA
79
TNM system metastasis interpretation
* MX: cannot be measured * M0: none * M1: metastasis present
80
0-IV CA staging
* Stage 0 * abnormal cells, no spread * AKA carcinoma in situ (CIS) * could become cancer * Stages I-III * CA present * ↑ number = bigger tumor, more invasion * Stage IV: cancer has spread
81
other cancer staging
* **in situ:** abnormal cells, no CA or spread * **localized:** no spread * **regional:** spread to nearby structures * **distant:** spread to distant structures * **unknown:** not enough info to stage
82
cachexia
dramatic wt loss, muscle wasting
83
general S/Sx in cancer pts
* anorexia * cachexia * fatigue * lethargy * weakness * pain * massess
84
S/Sx with metastasis
* discomfort elsewhere * lymphadenopathy * distant masses * abd swelling * bone pain or Fx * confusion or personality change * incontinence * vision changes * loss of balance * HA * Sz
85
cancer Tx options
* chemo * radiation * surgery * stem cell/bone marrow transplant * biological therapy * photodynamic therapy * complementary alternative medicine (CAM)
86
chemo therapy indication
CA spread beyond localized area
87
chemotherapy selectivity
has some, but damages healthy cells, too
88
chemo MOA
damages DNA, stopping or slowing fast-growing cells
89
Chemo is most successful as part of _____ therapy.
combination
90
Most chemo agents are _____ and \_\_\_\_\_.
* cytotoxic * teratogenic
91
AE of chemo: anemia
* lab values * RBC \< 3.8 million/μL * Hgb \< 11.5 g/dL * Hct \< 34% * S/Sx * extreme fatigue * pallor * dizziness * SOB
92
pt education for anemia
* schedule rest periods * energy-saving measures * possible Tx * O2 therapy * erythropoietic meds * antianemic meds * transfusion (pRBCs)
93
AE of chemo: immunosuppression/neutropenia
* normal ANC: 1500-8000/μL * normal WBC: 3,000-12,000/μL * main concern: infection * may not have fever; even slight fever is big problem
94
AE of chemo: thrombocytopenia
* normal Plt: 150,000-450,000/μL * main concerns * bleeding * **hemorrhagic cystitis** * interventions * fall precautions * bleeding precautions * Plt transfusion
95
bleeding precautions
* electric shaver * no ASA * needles * small guage * ↓ sticks * protect from injury * soft toothbrush
96
pancytopenia
low RBCs, WBCs, and Plt
97
nadir
* lowest point * in chemo * onset: 7-12 days after Tx * **HIGHEST RISK OF INFECTION** * duration: 5-7 days
98
alopecia
* hair thinning or loss * in chemo * onset: 7-10 days after first Tx * regrowth ~ 1 mo after last Tx
99
AE of chemo: mucositis
* inflammation of mucous membranes from mouth to stomach * includes stomatitis (mouth) * interventions * mouthwashes * anesthetic, antifungal, coating * saline rinse * lubricants for xerostomia * soft toothbrush * rinse AC and PC * soft, bland foods * avoid * ETOH * tobacco * glycerin
100
CINV
chemo-induced nausea and vomiting
101
AE of chemo: CINV and anorexia
* meds * ondansetron: serotonin blocker * in combo with * corticosteroids * phenothiazines (compazine, phenergan) * diphenhydramine * interventions * mouth care to ↑ appetite * small meals * cold foods * uncover meal away from pt * **assess for dehydration**
102
AE of chemo: peripheral neuropathy
* early S/Sx: symmetrical, distal to proximal * burning * tingling/pins-and-needles * numbness * redness * sensitivity to extreme temps * difficulty w/ fine motor skills * later S/Sx * loss of taste * orthostatic hypotension * constipation * can → sensory or motor dysfunction * cause: nerve damage * pt education: protect skin, avoid falls/injuries
103
chemo nursing interventions
* meds for pain, CINV, infection, etc. * monitor for SE * intervene PRN * regular med reconciliation * address psychosocial needs * pt and family education
104
teletherapy
external radiation therapy
105
brachytherapy
* internal radiation therapy * radiation source in direct contact with tumor * placed in vagina, prostate, abdomen, etc.
106
teletherapy regimen
* daily doses for set period * skin marked for guidance
107
AE of teletherapy
* extreme fatigue * dysgeusia * injury to skin, mucous membranes * hair loss
108
interventions for extreme fatigue
* schedule rest * gentle exercise
109
interventions/pt education for dysgeusia
* avoid red meat, other distasteful foods * gum, mints * try new flavors * plastic utensils * drink w/ meals
110
dysgeusia
altered taste
111
interventions for injury to skin
* wash w/ mild soap and water and pat dry * wear soft clothing * avoid sun, heat * only use prescribed creams/ointments * no powders
112
interventions for radiation injury to mucous membranes
* mucositis/stomatitis * prescribed mouthwashes * avoid ETOH, tobacco * bland, soft, smooth foods * small bites/meals * high-calorie and -protein * gastroenteritis * meds * abx * antidiarrheals * steroids * opioids * bland, lactose-free, low-fat diet
113
pt education for brachytherapy
body wastes are radioactive until isotope is eliminated
114
nursing considerations for brachytherapy
* private room * door sign * visitors * ≤ 30 min * ≥ 6 ft from pt * restrict: PG or \< 18 yo * wear lead apron * face pt * have lead container, tongs for devices that could fall out
115
types of surgeries for CA
* prophylactic * diagnostic * curative * cytoreductive (debulking) * palliative * second-look * reconstructive/rehabilitative
116
purpose of stem cell/bone marrow transplant
to replace bone marrow destroyed by CA or chemo/radiation
117
allogeneic stem cell/bone marrow transplant considerations
* at risk for GvHD * rejection can occur anywhere in the body
118
nursing care for stem cell/bone marrow transplant
* anti-rejection meds * protection from infection * monitor for SE/complications * GvHD * graft failure * infection * hepatic veno-occlusive dz (VOD) * interstitial pneumonitis
119
GvHD
graft-versus-host dz
120
VOD
* hepatic veno-occlusive dz * possible complication of stem cell/bone marrow transplant * AKA sinusoidal obstruction syndrome (SOS)
121
biological therapy
* modify pt's biological response to tumor cells * types * antitumor * improved immune fxn
122
biological therapy: interleukins
* seek and destroy * SE * chills * fever * fatigue * **confusion** * **NVD** * **↓ BP** * rare * arrhythmias * CP * ↑ dose must be given in hospital
123
biological therapy: interferons
* slow cell division, boost immune attack on CA cells * SE * chills * fever * fatigue * **HA** * **↓ appetite** * **N/V** * **↓ WBC** * **skin rash** * **thinning hair** * rare: PNS/CNS damage
124
mAbs
monoclonal antibodies
125
biological therapy: mAbs
* lab-produced antibodies * mimic immune system * SE * fever * chills * **weakness** * **HA** * **NVD** * **↓ BP** * **rashes** * **allergic rxn** * ↑ dose must be given in hospital
126
biological therapy: molecularly targeted therapy
* targets molecules involved in growth and spread of CA * SE * rash * dry skin * nail changes * hair depigmentation * impaired * clotting * wound healing * ↑ BP * rare: GI perforation
127
nursing care for biological therapies
* ↑ dose should be in ICU * monitor for SE, allergic rxn * promote comfort * identify neuro and psychosocial manifestations early * **no topical steroids**
128
skin care for pts on biological therapy
* unscented moisturizers (if allowed) * mild soap * sun protection * no * swimming * topical steroids
129
hormonal manipulation (androgens/antiestrogens) SE
* chest/facial hair growth * menstruation stops * breasts shrink * fluid retenion * acne * hypercalcemia * liver dysfunction
130
hormonal manipulation (estrogen/progestin) SE
* men * thinning facial hair * smoother facial skin * body fat moves * gynecomastia * testicular/penile atrophy * bone loss * women * irregular menstruation * fluid retention * breast tenderness * both * bone loss * ↑ risk for clotting
131
photodynamic therapy
* photosensitizing agent + special light = cell death * photosensitizers and wavelengths specific to body area * process * photosensitizer injected * tumor exposed to light 24-72 hr after injection * photosensitizer absorbs light → chemical rxn * rxn destroys CA cells * usually outpatient * can be repeated or used in combo
132
complementary and alternative medicine for CA
* alternative medical systems * ayurveda * homeopathy * traditional Chinese medicine * biological * diet * herbs * vitamins * manipulative * massage * osteopathic * chiropractic * mind-body * yoga * imagery * meditation * spirituality * energy * reiki * biolfields * magnets * qigong
133
CAM
complementary and alternative medicine
134
oncologic complications/emergencies
* sepsis * DIC * SIADH * spinal cord compression * hypercalcemia * sueprior vena cava syndrome * tumor lysis syndrome * cardiac tamponade
135
DIC
disseminated intravascular coagulation
136
SIADH
syndrome of inappropriate antidiuretic hormone
137
SIRS
systemic inflammatory response syndrome
138
sepsis starts with ...
SIRS
139
systemic inflammatory response syndrome
* must have ≥ 2 of the following * T \> 38C or \< 36C * HR \> 90 * RR \> 20 * acute AMS * WBC \> 12,000 or \< 4,000 * hyperglycemia in absence of DM
140
sepsis Dx
2+ SIRS criteria + presence or suspicion of infection
141
septic shock Dx
sepsis + hypotension not reversed w/ ↑ volume
142
common DIC cause
gram-negative sepsis in pts w/ CA
143
consequences of DIC
* bleeding * organ failure via microvascular thrombosis
144
syndrome of inappropriate antidiuretic hormone
* abnormal production of ADH * diluted serum Na+ * usually ≤ 115-120 mEq/L * ↓ UOP * weakness * muscle cramps * ↓ appetite * fatigue * wt gain (fluid retention) * **→ pulmonary edema and HF** * Tx: hypertonic saline
145
spinal cord compression
* S/Sx * pain * weakness * loss of sensation * tingling * incontinence * constipation * foot drop * unsteady gait * Tx/interventions * ↑ dose corticosteroids (↓ swelling) * back brace
146
hypercalcemia
* serum Ca \> 10.5 mg/dL (critical: \> 14 mg/dL) * S/Sx * excessive thirst * frequent urination * stomach upset, N/V, constipation * bone and muscle pain * weakness * confusion * lethargy, fatigue * depression * rare * palpitations * fainting * arrhythmia * Tx: fluid intake, bisphosphonates, furosemide, calcitonin, pamidronate
147
superior vena cava syndrome
* compression/obstruction of SVC → ↑ pressure → edema * S/Sx * facial, upper estremity edema * SOB * HA * CP * facial plethora * NVD * chest vein distension
148
facial plethora
facial fullness
149
tumor lysis syndrome
* S/Sx * hyperkalemia * hyperuricemia * hyperphosphatemia * **hypocalcemia** * → heart, kidney damage * prevention: hydration, 3-4 L/day as tolerated * Tx * kayexolate * allopurinol, rasburicase * calcium carbonate
150
cardiac tamponade
* buildup of blood or other fluid in pericardial sac * S/Sx * → cardiogenic shock * dyspnea * **tachycardia** * tachypnea * pallor * cold extremities * hypotension * **NVD** * possible: pericardial friction rub, **muffled heart sounds** * Tx: pericardiocentesis * Dx: echo, CBC, ECG, CXR, CT, ABGs,
151
Professional nursing practice is the practice of _____ and delivery of _____ to meet the needs of \_\_\_\_\_. —Academy of Medical-Surgical Nurses
* practice of **nursing** * delivery of **care** * meet the needs of **society**
152
Professional nursing practice implies more than a _____ level of _____ in the professional role. —Academy of Medical-Surgical Nurses
more than a **competent** level of **performance**
153
Many [7] activities are included in professional nursing practice relative to the _____ of \_\_\_\_\_, including .... —Academy of Medical-Surgical Nurses
* **quality** of **care** * performance appraisal * collegiality w/ others in the profession * ethics * research and EBP * collaboration * education * resource management
154
professional responsibility
obligation nurses have to every pt
155
Professional responsibility requires nurses to be knowledgeable in what 10 areas?
* advance directives * advocacy * confidentiality * disruptive behavior * ethical practice * information security * information technology * informed consent * legal practice * pt rights
156
nursing role in pt rights
* ensure pt understands his or her rights * protect those rights during nursing care * advocate for pt
157
5 pt rights
* be informed about ALL aspects of care * take active role in decision-making * accept, refuse, or request modification to plan of care * receive competent care * be treated with respect
158
nursing role in advocacy
* ensure * pts know rights * pts have adequate info * orders are appropriate for care * assist with decision-making * mediate when others' actions aren't in pt's best interest
159
When assisting w/ pts' decision-making, a nursing should not _____ or \_\_\_\_\_.
**control** or **direct**
160
situations for advocacy
* end-of-life decisions (advance directives) * access to health care * protection of privacy * informed consent * substandard practice
161
nursing role in informed consent
* ensure * provider gave adquate info * provider answers/clarifies all questions * pt understanding * ***signed consent form present before pt is taken for procedure*** * ***witness*** pt signature * provider is to have pt sign consent form
162
legal practice principles/aspects
* providing safe and competent care * advocating for pt rights * providing care in your scope of practice * discerning responsibilities of nursing in relation to those of other staff members * providing care consistent w/ current standards * shielding yourself from liability * **KNOW YOUR NURSE PRACTICE ACT**
163
mandated reporting
* impaired coworkers * abuse * communicable dz
164
disruptive behavior
* incivility * lateral violence * bullying * cyberbullying
165
principles of ethical practice
* autonomy * beneficence * fidelity * justice * nonmaleficence * veracity
166
autonomy
ability of pt to make their own decision
167
beneficence
care in best interest of pt
168
fidelity
doing what you say you will
169
justice
fair treatment
170
nonmaleficence
obligation to cause no harm
171
veracity
duty to tell the truth
172
accountability
having an obligation to pts and being responsible for your actions
173
By going to work and accepting a patient assignment, you accept _____ for the pts.
responsibility
174
delegation
* transferring authority and responsibility to another team member to complete a task * you retain accountability for completion, outcome, and timeliness * requires supervision
175
assigning
transferring authority, accountability, and responsibility of pt care to another staff member
176
responsibilities of delegation
* clear directions * reassessment * evaluation of outcome
177
Who can RNs delegate to?
* other RNs * LPNs * UAPs
178
Who can LPNs delegate to?
* other LPNs * UAPs
179
Delegation allows for the most _____ use of everyone's time and \_\_\_\_\_.
* most **efficient** * time and **skills**
180
6 considerations when delegating
* predictability of outcome * potential benefit vs. harm to pt * complexity of care required * extent of problem-solving involved * appropriateness of task for delegatee * extent of interaction
181
components of delegation
* delegator * delegatee * acceptance of delegated task * ability * willingness * supervision, follow-up, and reassessment/evaluation
182
5 rights of delegation
* right task * right circumstance * right person * right direction and communication * right supervision and evaluation
183
right task
* should require little supervision * should be relatively noninvasive
184
right circumstance
* complexity of care should match delegatee's skill set * consider delegatee's workload
185
right person
* delegatee should be competent to complete task * task should be in delegatee's scope of practice
186
right direction and communication
* what data to collect * how to report it * specific task to be performed * expected results, timelines, and expectations for follow-up reporting
187
right supervision and evaluation of care
* delegator must supervise (directly or not) * monitor performance * provide feedback * intervene if necessary * evaluate pt and determine if goals are met
188
obstacles to delegation
* personal qualities and experience * resources
189
personal qualities and experience that can become obstacles to delegation
* poor communication * poor interpersonal skills * poor time management * lack of trust and confidence * insecurity * inexperience in delegation * inadequate organizational skills * belief that others are incapable * belief that you are indispensable
190
How can resources create obstacles to delegation?
* no one to delegate to * span of control * finances * educational resources * time
191
overdelegating
* burdens delegatees: don't overdelegate just because an employee is exceptional * can be a result of someone's insecurity to complete a task
192
delegation errors
* overdelegating * underdelegating * reverse delegation
193
underdelegating
* can be result of insecurity by manager * control freak/micromanager * lack of experience in delegation * difficulty assuming manager role
194
reverse delegation
* common form of ineffective delegation * occurs when someone w/ lower rank delegates to one w/ more authority * often happens w/ individuals who are new to job
195
What causes resistance to delegation?
* delegatee is overwhelmed: tasks from multiple sources * delegatee believes self to be incapable of task * inherent resistance to authority
196
what cannot be delegated
* nursing process * pt education * tasks that require nursing judgment
197
what can be delegated
tasks appropriate to skill and education of delegate
198
tasks to delegate to LPN
* reinforcement of teaching * trach care * suctioning * NGT patency check * administration of meds, enteral feeds * insertion of foley
199
tasks that can be delegated to UAP
* ADLs * baths * toileting * ambulation * PO feeding * positioning * specimen collection * I&O * VS
200
nursing process
* way of thinking about, strategizing about, and implementing solutions to improve pt status/outcomes * parallels scientific process * contains 5 steps
201
5 steps of nursing process
* assessment * diagnosis * planning * implementation * evaluation
202
purpose of the nursing process
framework to apply knowledge, skills, judgment, and experience to **formulate a nursing plan of care**
203
ADPIE
acronym for steps of nursing process
204
assessment
collecting data, subjective and objective
205
diagnosis
* clustering data * discriminating relevant from irrelevant data * identifying pt needs/problems
206
planning
* setting priorities * establishing goals (SMART) * identifying desired outcomes * determining interventions to meet goals
207
implementation
performing interventions identified in planning stage
208
evaluation
* determining if goals and outcomes * were met with planned interventions * are feasible * need more time
209
parts of assessment/data collection
* thorough physical assessment * pt Hx * labs/imaging * pt reports
210
purpose of nursing plan of care
* guides nursing care * documents pt care * accountability * quality assurance * liability * substantiates care provided for * payers * legal entities * accreditors
211
SMART
* acronym for guidelines setting goals in care planning * specific * measurable * attainable * relevant * timed * "The patient will do something specific in a measurable way that is attainable and relevant by specific timeframe."
212
aspects of planning in the nursing process
* separating actual from potential problems * prioritizing problems/needs * identifying goals * identifying nursing, provider, and other interventions to help meet goals
213
types of care planning
* comprehensive * ongoing * discharge
214
comprehensive planning
based on full head-to-toe assessment and pt interview (usually admission data)
215
ongoing planning
* new info w/ each shift or as available * update, modify, and individualize care plan
216
discharge planning
* learning and anticipating pt's and family's needs after discharge * should begin during admission
217
prioritizing
separating actual from potential problems/needs
218
Maslow's hierarchy of needs
1. physiological 2. safety and security 3. love and belonging 4. self-esteem 5. self-actualization
219
ABC framework
* airway * breathing * circulation * disability * exposure
220
airway priority
* necessary for breathing * look for blockage/obstruction * listen for stridor/wheezing * consider exposure (smoke inhalation)
221
breathing priority
* necessary for oxygenation of blood * auscultate breath sounds for crackles, wheezing, rhonchi * check SpO2 * common problems: COPD, asthma, pulmonary edema
222
circulation priority
* monitor BP * consider volume, pressure changes * IVF * vasopressors * diuretics * dialysis * trauma
223
physiological needs beyond ABC
* order depends on number and severity, but generally: 1. food/fluid 2. neurosensory 3. elimination 4. rest/activity 5. pain/discomfort 6. hygiene
224
goal time frames and their purposes
* short-term: end of clinical day; baby steps toward long-term goal * long-term: by discharge; aimed at functionality outside hospital
225
nursing interventions
* nurse-initiated/independent * don't need provider order * e.g. turn Q2H
226
provider interventions
* dependent interventions * by order or facility protocol * e.g. meds, blood products, treatments, etc.
227
collaborative interventions
* done in collaboration w/ other health professionals * e.g. wound care, PT, OT, speech therapy, etc.
228
teaching interventions
instruction or education of pt and family
229
Interventions should be \_\_\_\_\_, include _____ to meet the goals, and be done on a \_\_\_\_\_.
* be **specific** * include **actions** * on a **schedule**
230
using priorities during a shift
* develop a plan * complete highest priority tasks first * finish one task before beginning another * reprioritize throughout shift based on new info
231
**prioritization principles** \_\_\_\_\_ before local actual before \_\_\_\_\_ consider pt/family \_\_\_\_\_ recognize and respond to \_\_\_\_\_ differentiate _____ from expected know procedural \_\_\_\_\_
* systemic * potential * priorities * trends * emergent * standards
232
other frameworks
* risk reduction * assess safety risks * eliminate greatest risks first * survival potential * mass casualty, disaster triage * priority: pts w/ reasonable chance for survival with prompt intervention * least restrictive * implement least restrictive/invasive interventions first * move to more restrictive/invasive PRN * acute vs. chronic * urgent vs. nonurgent * stable vs. unstable
233
Evaluate priorities \_\_\_\_\_, remain \_\_\_\_\_, and don't fall into _____ to the "squeaky wheel."
* evaluate **constantly** * remain **flexible** * **responding** to the "squeaky wheel"
234
antigen
toxin or other foreign substance that induces an immune response, esp. production of antibodies
235
antibody
blood protein produced in response to and counteracting a specific antigen
236
autoimmunity
process whereby a person develops an inappropriate immune response to healthy, normal tissues
237
ANA test
identifies if antinuclear antibodies are present in blood, which could indicate autoimmune d/o
238
ANA
antinuclear antibodies
239
In addition to protection, immunity plays a role in _____ of _____ tissues.
**repair** of **damaged** tissues
240
immunity
* protection from illness or dz * maintained by body's physiologic defense mechanisms
241
leukocytes
* WBCs * stimulate inflammatory response and protect against various infections and foreign antigens
242
types of leukocytes
* neutrophils * lymphocytes * monocytes * eosinophils * basophils
243
differential
percentages of types of total circulating WBCs
244
WBC expected reference range
5,000-10,000/mm3
245
leukopenia
* total WBC \< 4,000/mm3 * causes * drug toxicity * autoimmune dz * bone marrow failure * overwhelming infection
246
leukocytosis
* total WBC \> 10,000/mm3 * causes * inflammation * infection * some malignancies * trauma * dehydration * stress * steroids * thyroid storm
247
Someone may have persistently high _____ count after splenectomy.
**WBC** count
248
neutropenia
* ANC \< 2,000/mm3 * \< 1,000/mm3 = neutropenic precautions are essential * ↑ risk of infection * causes * viral infections * overwhelming bacterial infections * radiation and chemotherapy
249
ANC
absolute neutrophil count
250
neutropenic precautions
* no visitors * no live plants * no fresh fruits and veggies * avoid contamination from pt's own bacterial flora * no rectal temp * no IM injections
251
left shift
* increase in immature neutrophils (bands or stabs) that occure in acute infection * immature cells incapable of phagocytosis
252
viral infections that commonly lead to neutropenia
* Epstein-Barr * CMV * hep A and B * parvovirus * flu * measles
253
segmented neutrophils
mature neutrophils
254
banded neutrophils
immature neutrophils
255
immunocompetence
* ability of the body's immune system to respond to pathogenic organisms and tissue damage * inflammation response + cell-mediated + antibody-mediated processes
256
body structures involved in immunity
* mucous membranes * tonsils * lymph system: vessels, nodes, spleen * thymus * skin * bone marrow
257
All parts of the immune system involve \_\_\_\_\_.
WBCs
258
self vs. non-self
immune system uses proteins on cell surface (human leukocyte antigens) to determine whether a cell is foreign or not
259
human leukocyte antigens
protein sequence on cell surface determined by DNA and unique to each person
260
bone marrow purpose
site for formation of all blood cells and majority of immune cells
261
pluripotent
* having multiple functions * as in stem cell, giving rise to multiple types of cells
262
innate/natural immunity
* barrier: skin, mucous membranes * inflammation
263
adaptive immunity
* antibody-mediated immunity * cell-mediated immunity
264
inflammatory response
* immediate, but short-term immune response * no lasting immunity to repeat exposure
265
risk factors for changes in immunity
* genetic risk for ↑ or ↓ immunity * OA * low socioeconomic status * nonimmunized * chronic illnesses that weaknes immunity * chronic drug therapy * substance abuse d/o
266
SCID
* severe combined immunodeficiency * congenital * missing important WBCs
267
meds that can weaken immunity
* steroids * chemo * other CA drugs * anti-rejection meds
268
environmental factors that can weaken immune system
* ETOH * smoking * poor nutrition
269
viruses that can weaken the immune system
* HIV * flu * mono * measles
270
The immune system is healthiest in what age groups?
20s and 30s
271
consequences of and pt education for decreased immune response
* sucsceptible to multiple types of infections * avoid large crowds; wash hands
272
consequences of excessive immune response
* allergies: hypersensitivity rxn * autoimmune rxn or dz: remission vs. cure
273
conditions caused by overactive immune system
* asthma * eczema * allergic rhinitis
274
eczema
allergen → atopic dermatitis
275
asthma
immune rxn in lungs → wheezing, coughing, trouble breathing
276
asthma triggers
* allergens: mold, pollen * irritants: smoke
277
allergic rhinitis
* indoor or outdoor allergens evoke immune response in upper airway * sneezing, runny nose, sniffling, swelling of nasal passages
278
inflammation
* immediate, short-term immune response * does not result in future immunity to same organism/injury * response varies by injury * cardinal signs: edema, erythema, warmth, pain, ↓ fxn
279
major cells involved in inflammatory response
* Plt * mast cells * neutrophils * macrophages * monocytes * basophils * eosinophils
280
Plt fxn in inflammatory response
* initial response to stop bleeding * release messengers to attract other immune system cells
281
mast cell fxn in inflammatory response
* hang out near possible pathogen entry points * immediately open and release contents on contact w/ pathogens * bring other cells to site of entry
282
neutrophil fxn in inflammatory response
* short lifespan, high number * kill pathogens via phagocytosis
283
macrophage fxn in inflammatory response
* phagocytosis * secretion of cytokines to recruit specific immunity cells to site
284
monocyte fxn in inflammatory response
* monocyte = immature macrophage * migrate from bone marrow to site of pathogen when signaled
285
basophil fxn in inflammatory response
* release histamine * cause manifestations of inflammation
286
eosinophil fxn in inflammatory response
* release amines during allergic rxn * some phagocytic properties * major role in destruction of parasites
287
stages of acute inflammation
* Stage I: vascular * Stage II: cellular exudate * Stage III: tissue repair/replacement
288
vascular stage of acute inflammation
* histamine and kinin release * → constriction of veins, dilation of arterioles * purpose: ↑ blood flow to area * capillaries become leaky * → inflammatory cells, mediators to injury site * → edema * macrophages start phagocytosis and send cytokines * → more WBCs and neutrophils come to site
289
cellular exudate stage of acute inflammation
* neutrophils arrive * exudate (purulent drainage) forms from debris * most protection from phagocytosis * more monocytes produced, send signals to continue response * production of neutrophils continues
290
tissue repair/replacement stage of acute inflammation
* body begins to fill in gaps in injured tissue * may → * scar tissue * ↓ fxn of tissue
291
chronic inflammation
* self-perpetuating * duration: wks, mos, yrs * often * asymptomatic * switches away from neutrophil involvement * can → DNA damage, certain types of CA * common causes: irritants * foreign bodies: viruses (e.g. HPV), fungi * obesity: production of a cytokine used in inflammation
292
Chronic inflammatory dz are the most significant cause of _____ in the world.
death
293
3 diseases that can be caused by chronic inflammation
* heart dz * DM * CA
294
humoral immunity
antibody-mediated immunity
295
antibody-mediated immunity
* process: B cells * are sensitized/imprinted by contact w/ specific antigen * produce antibodies * divide and make memory B cells for future immunity
296
Total population of lymphocytes in immunocompetent person can be in the \_\_\_\_\_.
millions
297
B and T cells
lymphocytes
298
B cells
* lymphocytes that begin as stem cells in bone marrow * enter blood circulation and mature in * spleen * lymph nodes * tonsils * mucosa of GI tract
299
B cells attack invaders _____ cells.
**outside** cells
300
T cells attack _____ cells.
**infected** cells
301
process of specific immunity development
* ***(B cells)*** * exposure * antigen recognition * sensitization * antibody production/release * antibody-antigen binding * inactivation of organism w/ antigen * sustained immunity
302
steps in inactivation of organism w/ antigen by B cells
* allutination * lysis * complement activation and fixation * precipitation * inactivation
303
antibody types
* IgG * IgA * IgM * IgE * IgD
304
immunoglobulin
antibody
305
Ab
antibody
306
IgG
most abundant and involved Ab
307
IgA
found in blood, body secretions
308
IgM
* largest * first Ab produced during primary response
309
IgE
* mediator in allergic responses * defends against parasites
310
IgD
* low serum concentration * found mostly on surface of developing B cells
311
cell-mediated immunity
* major cells * T lymphocytes * natural killer (NK) cells * dendritic cells * hang out in secondary lymph organs and wait for exposure to antigens
312
classes of T cells
* helper (Th, T4) * suppressor (Ts, T8) * cytotoxic (Tc)
313
Th cell fxn
activate macrophages, Tc cells, and B cells
314
Ts/T8 cell fxn
control immune response to protect host
315
Tc cell fxn
kill cells with antigen they've been exposed to
316
T cell origin
thymus
317
NK
natural killer (cells)
318
natural killer cell fxn
direct cytotoxic effects on some non-self cells without prior sensitization
319
DCs
dendritic cells
320
dendritic cell fxn
process antigen material and present it on cell surface to T cells of immune system
321
cytokines
* small hormones produced by WBCs * WBCs → monokines * T cells → lymphokines * regulate action of immune system * may have multiple roles or single role
322
antigen-presenting cells
* APCs * cells that process antigen material and present it on cell surface to Th cells * mostly done by * B cells * DCs * macrophages
323
cell-mediated immunity process
* APCs present to Th cells * Th cells recruit * Th1 cells activate macrophages and Tc cells * Th2 cells activate B cells * T memory cells formed for future immunity
324
CMI protects by differentiating _____ from \_\_\_\_\_, and most easily recognizes \_\_\_\_\_.
* **self** from **non-self** * recognizes **CA**
325
CMI
cell-mediated immunity
326
CMI can also recognize some _____ self cells.
infected
327
hypersensitivity
* essentially an overreaction to an antigen * four major types that can occur alone or with one or more others
328
types of hypersensitivity rxns
* Type I: rapid/immediate * Type II: cytotoxic * Type III: immune complex * Type IV: delayed
329
Type I hypersensitivity rxn
* rapid/immediate * ↑ production of IgE in response to antigen * excessive release of histamine from basophils, eosinophils → * anaphylaxis * allergic asthma * conjunctivitis * rhinitis * pruritis * edema * rash * urticaria * angioedema * methods of exposure * inhalation * ingestion * injection * contact
330
5 common primary allergens and their cross-reactant allergens
* pollen: apple, hazelnut, carrot, kiwi, apricots, peaches * mites: crustaceans * latex: exotic fruits such as banana, avocado, kiwi * bird dander: egg yolk * cat dander: pork
331
Type II hypersensitivity rxn
* Ab directed against foreign antigen on self cell * usually attacks a specific tissue type * mainly IgG or IgM * play a role in several autoimmune diseases
332
examples of Type II hypersensitivity rxn
* autoimmune hemolytic anemia * hemolytic dz of the newborn (Rh dz) * blood transfusion rxn * myasthenia gravis (acetylcholine receptor)
333
AIHA
autoimmune hemolytic anemia
334
Type III hypersensitivity rxn
* immune complex rxn * process * excess antigens → formation of immune complexes in blood * immune complexes precipitate, wedge into vessels in organs → inflammation and damage * types/conditions * serum sickness * SLE * RA
335
SLE
systemic lupus erythematosis
336
RA
rheumatoid arthritis
337
Type IV hypersensitivity rxn
* delayed * T cells recruit macrophages to attack hrs or days after exposure * examples * poison ivy * latex * graft rejection * positive TB skin test * sarcoidosis * IV drug rxn (e.g. abx)
338
autoimmunity
* condition in which immune system recognizes proteins on self cells as foreign * body attacks self cells w/ that protein * can be Ab- and/or cell-mediated * no cure
339
mechanisms of autoimmunity
* genetics: certain HLAs are more susceptible * infections * various viruses and bacteria can contribute * viruses or bacteria share epitope w/ host cells * adaptive immune system forms response to antigen w/ T and B cells * immune system attacks all cells w/ that epitope
340
rheumatoid arthritis
* systemic AID affecting mostly synovial joints * → damage to joint and cartilage * also affects * blood vessels * pleurae * pericardium * iris and sclerae * typically affects upper joints first
341
pathophysiology of RA
* body makes Abs that attack synovium, articular cartilage, joint capsule, ligaments, and tendons * thought to be initiated by CD4 cells * CD4s recruit mediators that attack synovial membrane * also involves B cells * process * synovium thickens * fluid accumulates * pannus forms * more blood vessels form in synovial membrane → perpetuation of inflammatory response * result: permanent damage to bone * early Dx and Tx can prevent damage
342
risk factors for RA
* female gender * age: 20-50, then OA * genetics * exposure to Epstein-Barr * possible other environmental factors: smoke, silica, insecticides * exacerbations linked to stress
343
early manifestations of RA
* generalized weakness, fatigue * anorexia, wt loss * persistent low-grade fever * joints: stiff, red, painful, tender, swollen, warm * usually in hands first * pain at rest and with movement
344
late manifestations of RA
* progressive inflammation * ↑ pain * morning stiffness (gel phenomenon) lasting 45 min to several hrs * joints feel soft, look puffy (synovitis and effusions) * joint deformity, lack of fxn * ulnar deviation * swan neck * boutonniere
345
labs for RA
* RF: Abs present in connective tissue dz (IgG, IgM) * ANA: Abs targeted at host DNA * anti-CCP antibodies: specific to RA, + for most RA pts * ESR: measure of general inflammation; repeated w/ Tx * CRP: possible sub for ESR * serum complement proteins: lower in RA, other AIDs * HLA tissue typing (HLA-B27 antigen) * CBC: ↑ WBCs during exacerbation; anemia (iron unavailable)
346
RF
rheumatoid factor
347
anti-CCP antibodies
anti-cyclic citrullinated peptide antibodies
348
ESR
erythrocyte sedimentation rate
349
diagnostics for RA
* X-ray * CT * MRI * arthrocentesis * bone scan
350
skeletal scintigraphy
bone scan
351
expected findings in arthrocentesis for RA
↑ WBCs and RF
352
pharm Tx for RA, in order of use
1. NSAIDS 2. Cox-2 inhibitor 3. corticosteroids 4. DMARDs
353
NSAIDs for RA
* first-line med * pain and fever relief, anti-inflammatory * often w/ H2 blocker to protect GI; monitor for bleed * experimentation w/ types usually needed
354
Cox-2 inhibitor for RA
* celecoxib * ↓ GI Sx * ↑ cardiac dz risk
355
corticosteroids for RA
* prednisone * fast anti-inflammatory * often used in high dose for flares * **not for long-term** * SE * immunosuppression * osteoporosis * hyperglycemia * **cataracts**
356
DMARDs for RA
* antimalarial: hydroxychloroquine * abx w/ anti-inflammatory properties: minocycline * sulfonamide: sulfasalazine * biological response modifiers * etanercept * infliximab * adalimumab * cytotoxic meds * methotrexate * leflunomide * azathioprine * cyclophosphamide
357
hydroxychloroquine for RA
* ↓ pain * used with mild dz
358
minocycline for RA
* anti-inflammatory properties * used for mild RA
359
sulfasalazine for RA
* ↓ pain and swelling * prevent damage * ↓ risk of long-term disability
360
biological response modifiers for RA
* slows progression * typically given w/ methotrexate * risk of immunosuppression * bing w/ part of inflammatory process to ↓ response * must rule out TB and MS (can cause flare) * lab monitoring: TB, hep B, LFTs, CBC, hCG
361
methotrexate for RA
* folic acid antagonist * blocks several enzymes in immune response * 1x/wk * relatively inexpensive * onset: 4-6 wks * avoid PG
362
leflunomide for RA
* ↑ mobility * ↓ joint swelling * severe SEs * alopecia * diarrhea * ↓ WBCs, Plt * liver damage
363
MTX
methotrexate
364
azathioprine or cyclophosphamide for RA
* immunosuppressants * interrupt immune process * ↓ inflammation * slow joint damage
365
skin cancer pathophysiology
* uncontrolled growth of abnormal cells in specific epithelial cells of skin * types * squamous * basal * melanocytes
366
skin cancer risk factors
1. exposure to UV rays * fair complexion * age * being male * family Hx * chemical exposure * radiation exposure * living in upper elevations or near equator * presence of many moles
367
skin cancer prevention
* primary * ↓ sun exposure * no tanning beds * secondary/screening * early detection * body spot map * frequent skin checks (self and/or provider)
368
basal cell carcinoma
* most common skin CA * growth * slow * rarely metastasizes * can cause local tissue destruction * presentation * generally painless * usually in sun-exposed areas (head, face, neck) * nodular lesion most common
369
squamous cell carcinoma
* second most common skin CA * appearance: firm, crusty, or ullcerated * vulnerable areas * sun-exposed areas (head, neck lower lip) * (chronic irritation) scars, irradiated skin, ulcers * growth * rapid invasion * metastasis in 10% * larger tumors more likely to metastasize
370
malignant melanoma
* **deadliest** form of skin cancer * growth: metastasizes * presentation * irregular red, blue, white, or dark-colored lesions * almost always a change in a skin lesion over months * vulerable areas: **all** * upper back * lower legs * soles of feet * palms
371
skin CA assessment
* Hx * skin injury * sunburns/exposures * mole or other lesion removals * **assess all areas** of skin, including in hair * **ABCDE** * asymmetry * borders * color * diameter * evolving
372
ABCDE for skin CA
* asymmetry * borders * color * diameter * evolving
373
asymmetry
when half the mole doesn't match the other
374
border
when the border of the mole is ragged or irregular
375
color
when color of mole varies throughout
376
diameter
if the mole's diameter is larger than a pencil eraser
377
evolving
the appearance of the mole changes over time
378
skin CA labs and Dx
* no blood tests * Bx is gold standard
379
types of Bx for skin CA
* shave * punch * incisional * excisional
380
incisional Bx
part of tumor is removed for testing
381
excisional Bx
all of tumor is removed, then tested
382
nonsurgical management of skin CA
* cryosurgery * topical chemo * radiation
383
surgical management of skin CA
* curettage and electrodessication ([video](https://www.youtube.com/watch?v=IpmNtNMLz80)) * excision * **gold standard: Mohs excision** * removal of nearby lymph nodes and tissue ([sentinel node Bx](https://www.mayoclinic.org/tests-procedures/sentinel-node-biopsy/multimedia/sentinel-node-biopsy/vid-20084727))
384
Mohs excision
* gold standard for skin CA excision * surgeon removes visible CA and small margin of surrounding healthy tissue * allows surgeon to verify all CA cells are removed at time of surgery
385
skin CA nursing implications
* interventions based on AE of Tx * surgical site care * monitor for complications * pt education * tests * Tx and AE * meds * ways to ↓ UV exposure
386
lung CA
* among most common forms of CA * most common cell types * non-small cell * small cell * survival * 5-year: 16% * w/ early detection, small tumor: 52% * most detected late * generally poor prognosis
387
lung CA patho
* most are bronchogenic * bronchial tumor → obstruction of bronchus * lung tumor → obstruction of alveoli, nerves, blood vessels, lymph vessels * can metastasize to surrounding tissue, blood, lymph system
388
lung CA risk factors
* tobacco smoke * smoking: 85% of deaths * second-hand smoke exposure * radiation exposure * environmental exposure → chronic inflammation * pollutants * irritants
389
lung CA primary prevention
* no smoking * use appropriate mask to minimize exposure to pollutants/irritants
390
secondary prevention for lung CA
annual CT for those at high risk
391
clinical manifestations of lung CA
* Sx * chronic cough * chronic dyspnea * fatigue * chest wall pain * signs * hoarseness * chest wall masses * fingernail clubbing * low SpO2 * visible massess or fluid on imaging * late * wt loss, anorexia, cachexia * hemoptysis
392
lung CA labs and diagnostics
* CXR * chest CT * PET * pulmonary fxn test * cytology * sputum culture * thoracentesis (for pleural effusion) * ABGs * Bx * bronchoscopy * CT-guided
393
nonsurgical Tx for lung CA
* chemo * radiation * targeted therapy * photodynamic therapy * radiofrequency ablation
394
chemo for lung CA
mostly for SCLC
395
purpose of radiation in lung CA
* shrink tumor → assist w/ Tx or palliate * primary Tx for high-risk pts
396
photodynamic therapy for lung CA
* used in bronchial tumors via scope * for small, easily accessed tumors
397
radiofrequency ablation for lung CA
electric current delivered directly to tumor via CT-guided needle
398
surgical Tx for lung CA
* wedge resection * segmental resection * lobectomy * pneumonectomy
399
wedge resection for lung CA
very small area of tumor near surface of lung is removed
400
segmental resection for lung CA
removal of one or more lung segments w/ attached bronchiole and alveoli
401
lobectomy
removal of entire lobe of lung
402
pneumonectomy
removal of entire lung
403
post-op care for lung CA pts
* monitor respiratory status * tracheal deviation * dyspnea * SpO2 * coloration * maintain chest tube/drain * patency/adequate drainage * monitor drainage color, amount * insertion site * empty container * incisional site care * encourage * ambulation * incentive spirometry * T, C, DB exercises w/ splinting
404
nursing implications for lung CA Tx
* care of SE r/t Tx * maintain airway, suction PRN * high Fowler's * O2 therapy * bronchodilators, steroids * fluids * anxiety ↓ * support * palliative care
405
leukemia
* cancer of bone marrow * most common malignancy in children and young adults
406
leukemia patho
* uncontrolled proliferation of immature WBCs * CA cells replace normal cells in marrow → ↓ healthy WBCs, RBCs, and Plts
407
leukemia classifications
* speed of progression * acute * chronic * type of blood cells affected * lymphocytic/lymphoblastic * myelogenous
408
leukemia risk factors
* (exact cause unknown) * genetics * previous chemo * ionizing radiation * certain chemicals * immunodeficiency * smoking
409
leukemia clinical menifestations
* fever/chills * persistent fatigue, weakness * frequent or severe infection * wt loss w/o trying * lymph node swelling * enlarged liver or spleen * easy bleeding/bruising * recurrent epistaxis * petechiae * excessive sweating, esp. at night * bone pain or tenderness
410
leukemia labs, diagnostics
* bone marrow aspiration and Bx * ↑ immature leukemic blast cells * determines cell type involvement * CBC * WBC: ↑, ↓, or WNL * ↓ H&H * ↓ Plt * INR, aPTT: ↑ w/ acute types * CXR, CT, PET, bone scan to check for metastasis
411
leukemia Tx
* chemo * three phases * induction * consolidation * maintenance * may require re-induction * biologic response modifier (filgrastim) after chemo * bone marrow/stem cell transplant
412
induction therapy
* aggressive chemo Tx for leukemia * 4-6 wks in hospital * usually continuous chemo infusion
413
consolidation therapy
* second phase of leukemia chemo Tx * lower dosage * possibly different meds * about 6 mo
414
maintenance therapy
* third phase of leukemia chemo Tx * even lower doses * months to years to prevent relapse
415
bone marrow/stem cell transplant for leukemia
* bone marrow destroyed using full-body radiation or chemo * marrow replaced with healthy cells via infusion * pt at high risk for infection and bleeding until transplanted cells start working
416
nursing implications for leukemia pts
* pancytopenia * interventions based on AE * monitor for complications (GvHD) * pt education * tests * Tx * AE * meds
417
lymphoma types
* Hodgkin's (HL) * non-Hodgkin's (NHL)
418
HL
Hodgkin's lymphoma
419
NHL
non-Hodgkin's lymphoma
420
Hodgkin's lymphoma
* contains Reed-Sternberg cells * population: teens and young adults, 50s-60s * progression * single node or chain of nodes * predictable metastasis, starting w/ closest nodes
421
non-Hodgkin's lymphoma
* no Reed-Sterberg cells * more common in **men, OA** * \> 65 subtypes * complicated Dx and classification * metastasis **unpredictable**
422
risk factors: HL
* mostly unknown * possibly viral infections or exposure to certain chemicals
423
risk factors: NHL
* gene damage * viral infections * radiation * AID * chemicals: ↑ incidence w/ exposure to pesticides, insecticides, dust
424
lymphoma S/Sx
* often asymptomatic * large, painless swelling of lymph node * NHL: multiple nodes * HL: usually starts in neck * may c/o * fevers \> 101.5 * night sweats * wt loss * infections * general malaise
425
lymphoma labs and diagnostics
* extensive testing required; difficult to classify * gold standard: **lymph node Bx** * CBC * r/o similar conditions * check for met to bone marrow (pancytopenia) * bone marrow Bx * staging, mapping, metastasis: CT, CXR, PET, bone scan
426
lymphoma Tx
* chemo * radiation * immunotherapy * NHL only: targeted therapy
427
nursing implications for lymphoma pts
* intervene based on AE of Tx * monitor for complications * pt education: tests, Tx, meds, AE
428
multiple myeloma
* cancer of plasma cells * accumulates in bone marrow, crowds out healthy cells
429
multiple myeloma patho
* cancerous plasma cells * create abnormal Abs (myeloma proteins)
430
M protein
* myeloma protein * abnormal Ab made by cancerous plasma cells
431
MM
multiple myeloma
432
MM risk factors
* OA: Dx usually ≥ 65 yo * male sex * African-American race (2x as common as caucasian) * Fm Hx * obesity * personal Hx of other plasma cell dz * monoclonal gammopathy of undetermined significance (MGUS) * solitary plasmacytoma
433
MM clinical manifestation
* varies and may be asymptomatic * bone pain, esp. spine or chest * weakness, numbness in legs * GI * nausea * constipation * loss of appetite * wt loss * abd pain * mental fog, confusion * fatigue * infections * GU * excessive thirst * renal dz/failure * polyuria
434
MM labs and diagnostics
* CBC * usually anemia * thrombocytopenia, leukopenia possible * chemistry * Cr to test kidney fxn * albumin: ↓ in MM * Ca: ↑ in advanced MM * lactic dehydrogenase: ↑ in advanced, poor prognosis * urine: M protein * bone marrow Bx * CT, PET, bone scan, MRI
435
Tx for MM
* chemo * bone-strengthening meds * immunotherapy * stem cell transplant * [management of bone damage](https://www.youtube.com/watch?v=bmYblbQv4dw)
436
nursing implications for MM
* interventions for AE of Tx * monitor for complications * pt education: tests, Tx, AE, meds
437
bone cancer
* sarcomas starting in osteoblasts or osteoclasts * common types * osteosarcoma * chondrosarcoma * Ewing's sarcoma
438
osteosarcoma
* most common * starts in bone cells * population * 10-30 yo or 60-70 yo * rare: middle age * male \> female * usually in arms, legs, or pelvis
439
chondrosarcoma
* second most common bone CA * sites: starts in any cartilage cells * trachea * larynx * chest wall * scapula * ribs * skull * population * rare: \< 20 yo * more common: 20-75 yo * men = women
440
Ewing's sarcoma of bone
* third most common bone CA * population * rare in adults \> 30 yo * most common in whites * rare in African- and Asian-Americans * sites * pelvis * chest wall * long bones of arms, legs
441
bone CA risk factors
* retinoblastoma ↑ risk * possible genetic tendency * multiple enchodromatosis ↑ risk for chondrosarcomas * Paget dz * radiation
442
enchondromatosis
cartilaginous bumps on bones
443
Paget dz
* pre-cancerous condition * → formation of abnormal bone tissue * affected bones become heavy, thick, brittle, and weak
444
bone CA clinical manifestations
* **pain in affected bone** (most common) * swelling of area around bone * Fx * numbness, tingling * wt loss * fatigue
445
bone CA labs and diagnostics
* Ca may be ↑ in blood, urine * CBC * ↑ alkaline phosphatas, lactate dehydrogenase * imaging * X-ray * bone scan * CT * MRI * PET * **Bx: definitive**
446
bone CA Tx
* surgery * radiation * chemo
447
surgery for bone CA
* type of surgery depends on type and severity * ranges from curettage with cryotherapy to amputation
448
radiation for bone CA
* most types not killed easily * requires high doses * used when * cannot be completely removed w/ surgery * positive margins found after excision
449
chemo for bone CA
usually for Ewing's sarcoma of bone, osteosarcoma, or metastatic bone CA
450
nursing implications for bone CA Tx
* interventions based on AE of Tx * peri-op care * monitor for complications * pt education: testing, Tx, AE, meds
451
colorectal CA patho
* most start as polyps, but not all polyps become cancer * **adenomatous polyps: pre-cancerous** * hyperplastic, inflammatory polyps mostly not cancerous * could become cancer if * \> 1 cm * \> 2 polyps * dysplasia present (abnormal, but not cancerous cells)
452
colorectal CA patho
* polyp → cancerous → grows into wall of colon/rectum * innermost layer → outer layer * 95% are **adenocarcinoma** * site: anywhere in colon or rectum * proximal: ascending, transverse * distal: descending, sigmoid * most common: **rectosigmoid**
453
colorectal CA risk factors
* colorectal: women \> men * rectal: men \> women * adenomatous polyps * age \> 50 * African-American descent * ulcerative colitis, Crohn's dz * diet ↑ fat and red meat, ↓ fiber * smoking * ETOH abuse * inactivity * HPV * family Hx
454
colorectal CA manifestations
* change in stool consistency * pencil-thin stools * blood in stool * hematochezia * melena * occult * cramps * mass * wt loss * fatigue * vomiting * abd fullness, distention, pain
455
hematochezia
bright red blood in stool
456
melena
black, tarry stool
457
colon CA labs and diagnostics
* CBC: ↓ H&H * carcinoembryonic antigen (CEA): + * fecal occult blood test * colonscopy, sigmoidoscopy w/ Bx **(Bx definitive)** * CT, MRI * barium enema
458
CEA
cracinoembryonic antigen test
459
surgical colon CA Tx
* polypectomy: local excision during colonoscopy * abd-perineal resection: anus, rectum, and sigmoid colon removed * colectomy: all or part of colon and nearby lymph nodes removed * proctocolectomy: colon and rectum removed * reanastamosis: if not possible, will need ostomy: * colostomy * ileostomy * stoma: pink or red and moist * temporary or permanent
460
non-surgical Tx of colon CA
* chemo * adjuvant: extra chemo after surgery to ↓ risk of recurrence * targeted med therapy: monoclonal antibodies to inhibit growth * radiation
461
nursing implications for colon CA Tx
* interventions based on AE * peri-op care * monitor for complications * pt education * tests * Tx, AE * meds * ostomy care
462
impact of CA
* physical and psych health * quality of life * financial * family dynamics
463
plasmapheresis
process that filters blood, removes harmful Abs
464
therapeutic procedures for RA
* plasmapheresis * synovectomy * total joint arthroplasty
465
synovectomy
* excision of synovial membrane * types * open: ↑ morbidity * arthoscopic: incomplete removal
466
total joint arthroplasty
removal and replacement of articulating bone parts in joint
467
clinical remission rate for RA
50%
468
Within 10 yrs of definitive Dx and Tx, what percentage of RA pts are disabled?
30%
469
other Tx for RA
* ↓ pain and stiffness * rest * gentle, low-impact exercise when tolerated * ROM exercises (stiffness) * heat therapy * ice for ↓ edema * proper nutrition * CAM (usually anti-inflammatory) * fish oil * turmeric * glucosamine and chondroiton
470
nursing care for RA
* assist w/ ROM * heat for stiffness, pain * ice for edema * encourage gentle exercise * cluster care/activities to conserve energy * give meds properly * monitor lab values
471
pt education for RA
* S/Sx to report * fever * s/sx of infection * pain on inspiration * nutrition * high-protein * small, frequent meals * meds * SEs * importance of adherence * S/Sx of bleeding
472
other conditions RA pts commonly develop
* interstitial lung dz (ILD) * bronchiectasis * bronchiolitis obliterans
473
ILD
interstitial lung dz
474
interstitial lung dz
* any of a large group of diseases w/ different causes but the same or similar clinical and pathological changes * cause: chronic, nonmalignant, noninfectious dz of lower respiratory tract w/ inflammation, disruption of alveolar walls * manifestations * limited O2 transfer from alveoli to capillaries * dyspneic * first w/ exercise * later, even at rest * risk factors * ↑ RF and anti-CCP * smoking * age
475
bronchiectasis
* chronic dilation of a bronchus or bronchi * usually in lower portions of lung * caused by damaging effects of long-standing infection
476
bronchiolitis obliterans
* inflammation of the bronchioles * bronchioles and sometimes smaller bronchi are partly or completely obliterated by nodular masses * massess contain granulation and fibrotic tissue
477
complications of RA
* Sjogren's syndrome * secondary osteoporosis * vasculitis → organ ischemia * interstitial lung dz
478
Sjogren's syndrome
* dz → ↓ production of tears, saliva, vaginal secretions * can result from RA * can → * light sensitivity * blurred vision * corneal damage * Tx: eye drops, artificial saliva, vaginal lubricants
479
secondary osteoporosis
* cause: long-term glucocorticoid use * encourage * weight-bearing exercise * Ca and vitamin D supplements
480
vasculitis
* → * organ ischemia * infarction and necrosis of tissue * usually involves smaller arteries in * skin * eyes * brain * inflammation of arteries 2/2 deposition of immune complexes
481
SLE
systemic lupus erythematosus
482
lupus erythematosus
* vague early manifestations, many diagnostic challenges * series of remissions and exacerbations * still no definitive test * ANA usually +, but + is not exclusive to SLE
483
classifications of LE
* discoid (DLE) * systemic (SLE) * medication-induced
484
DLE
discoid lupus erythematosus
485
discoid lupus erythematosus
* only affects skin * scaling, red, macular, pruritic rash * some pts have arthritis and/or arthralgia
486
systemic lupus erythematosus
* affects skin and connective tissue of multiple organs * → multi-organ inflammation
487
medication-induced lupus erythematosus
* temporary * induced by * procainamide * hydralazine * isoniazid * goes away w/ D/C of meds
488
lupus patho
* autoimmune w/ likely environmental factors * autoantibodies, mainly attacking cell nucleus * → buildup of immune complexes in serum and organs * → initiation of inflammatory process, damage of organs w/ possible vasculitis
489
lupus risk factors
* female \> male: possibly linked to estrogen * 20-40 yo * minority race * genetics: some familial involvement
490
clinical manifestations of SLE
* fatigue * blurred vision * general pain * photosensitivity * joint pain * mostly small joints: hands, wrists, and knees * w/o deformity * anorexia * depression * fever * anemia * **butterfly rash** * alopecia * muscle atrophy * pleural effusion * pericarditis * hematuria * peripheral edema (lupus nephritis?) * CNS * sz * migraine * avascular necrosis of femur * tendon rupture
491
lupus nephritis
* inflammation (swelling or scarring) of small vessels that filter wastes in kidneys * can → peripheral edema
492
labs for LE
* CBC * BUN, creatinine * UA * immunologic * ANA * serum complement (C3, C4) * ESR * other labs for Abs
493
diagnostics for LE
* skin Bx for DLE * renal Bx * echo * other imaging based on affected organs/systems
494
Tx for LE
* NSAIDs * corticosteroids: topical and PO * hydroxychloroquine: ↓ absorption of UV light * immunosuppressants
495
nursing care for LE
* monitor * and treat pain * BP for HTN * renal fxn * respiratory status * provide small, frequent meals * pt education
496
pt education for LE
* avoid UV esposure, use sunscreen * avoid infection * S/Sx of renal failure * peripheral edema * SOB * ↑ fatigue * PG risk factors w/ lupus meds
497
S/Sx of renal failure for lupus pt
* hematuria * protein in urine (frothy/foamy) * edema * wt gain * ↑ BP
498
LE complications
* lupus nephritis * pericarditis ([friction rub](https://depts.washington.edu/physdx/audio/rub2.mp3)) * pleural effusion ([friction rub](https://depts.washington.edu/physdx/audio/pleuralr%5B1%5D.mp3))
499
scleroderma
* "hardening of skin" * AKA systemic slerosis * uncommon * induration of various body parts * **skin** mainly, but can also affect other body systems * lungs and kidneys (primary COD) * SubQ tissue * muscles * other organs * manifestations vary greatly
500
induration
* ↑ of fibrous elements in tissue * associated w/ inflammation * marked by loss of elasticity, pliability
501
scleroderma patho
* involves humoral (Ab) and cell-mediated immune responses * immune attack on body structures → inflammatory process * affected areas become hardened and fibrotic * common presentation: skin or microvascular changes * exact etiology unknown
502
3 processes that lead to scleroderma manifestations
* severe fibroproliferative vascular lesions of small arteries, arterioles * excessive, often progressive deposition of collagen and other ECM macromolecules in skin and internal organs * alterations of humoral and cellular immunity
503
ECM
extracellular matrix
504
3 types of scleroderma
* diffuse cutaneous systemic sclerosis * limited cutaneous systemic sclerosis (milder) * fulminant systemic sclerosis: rapid onset/progression
505
diffuse cutaneous systemic sclerosis
* over most of body * skin is thickened on trunk, face, and extremities
506
limited cutaneous systemic sclerosis
* milder form * limited to sites distal to elbows and knees * may involve face and neck * pts usually have CREST syndrome
507
CREST syndrome
* a variant of progressive systemic sclerosis * presence of * calcinosis * Raynaud phenomenon * esophageal dysfunction * sclerodactyly * telangiectasia
508
calcinosis
condition marked by abnormal deposition of Ca salts in tissues
509
Raynaud phenomenon
* intermittent vasospastic attacks of small arteries and arterioles of fingers * pallor → cyanosis (numbness, cold) → erythema 2/2 hyperemia (throbbing, paresthesia) * triggered by cold temps or emotion * associated w/ * scleroderma * SLE * Buerger dz * nerve entrapment * anorexia-bulimia
510
sclerodactylia
induration of the skin on toes and fingers
511
telangiectasia
* AKA spider veins * vascular lesion formed by dilatation of a group of small blood vessels * usually on face or thighs * causes: sun exposure, birth mark, CREST syndrome, etc.
512
dilatation
expansion of an organ or vessel beyond normal size
513
systemic sclerosis risk factors
* found in all races, all geographic areas * female 4-9x \> male * age 25-55 yo * Hx of connective tissue dz * some chemical exposures * for more severe prognosis * younger age * African descent * rapid progression of skin Sx * involvement * ↑ skin * pulmonary * cardiac * renal * anemia * ↑ ESR
514
clinical manifestations of scleroderma
* joint pain and stiffness * LES incompetence + ↓ esophageal peristalsis → * GERD complaints * dysphagia * aspiration pneumonia * hoarseness * hiatal hernia * painless, symmetric pitting edema * fingers, hands, forearms * → carpal tunnel syndrome * loss of skin elasticity: tight and shiny * Raynaud's phenomenon * fibrosis of myocardium and lung alveoli * stone face * malignant HTN (renal effect) * telangiectasia
515
Raynaud phenomenon is present in initial presentation for ___ of pts w/ scleroderma, and ___ develop it.
* 70% * 95%
516
labs for scleroderma
* general AID labs like SLE * findings like SLE * ESR * almost always normal * if ↑, usually poor outcome
517
diagnostics for scleroderma
* dependent on organ involvement * CT, X-ray, echo, EGD, colonoscopy * upper and lower GI series common
518
pharm Tx for scleroderma
* to slow progression * often unsuccessful * ID organ involvement early and treat * meds * systemic steroids + ↑ dose immunosuppressants * bosentan (endothelium receptor antagonists) for pulmonary arterial HTN * H2 blockers + antacids for GERD * NSAIDs for inflammation/joint pain * *future: tocilzumab (IL-6 antagonist)*
519
nursing care for scleroderma
* monitor and treat pain * mild soap, skin care * keep pt warm * esophageal involvement: collaboration w/ speech therapy, dietitian * small, frequent meals
520
pt education for scleroderma
* S/Sx of organ involvement * how to avoid Raynaud's * dietary: avoid foods that worsen GERD * meds * importance of adherence * take w/ food to avoid GI distress * avoid infection * stress, smoking can worsen Sx
521
complications of scleroderma
* fibrosis of * myocardium * lungs → pulmonary HTN * esophagus * intestines * renal failure * med-related * infection * cataracts
522
Systemic sclerosis has the highest case-specific _____ among AIDs, with pulmonary _____ and _____ and _____ crisis being the most frequent CODs.
* highest **mortality** * pulmonary **HTN** and **fibrosis** (ILD) * **renal** crisis
523
HIV
human immunodeficiency virus
524
AIDS
acquired immune deficiency syndrome
525
HIV/AIDS
* very deadly because of the way it attacks the body * HIV → AIDS * HIV: retrovirus w/ 3 stages
526
HIV patho
* enters body via blood, semen, or vaginal secretions * binds to CD4 molecule on surface to enter Th cells * hijacks replicative mechanisms of cell to produce billions of virus particles * new particles enter other Th cells and continue cycle * window period * undetectable for first 1-3 mo * can still infect others * loss of CD4+ Th cells → * opportunistic infections * neoplastic processes
527
What viruses commonly co-infect w/ HIV?
* hep B and C * human herpes virus 8 * HHV8 * AKA Kaposi sarcoma herpes virus (KSHV)
528
3 stages of HIV infection
* created by CDC * based on CD4+ cell counts * stages * I: acute infection * II: clinical latency * III: AIDS
529
HIV Stage I
* acute infection * 2-4 wks after infection * flu-like illness for a few wks
530
HIV Stage II
* clinical latency: inactivity or dormancy * asymptomatic/chronic * still active, but produces at low levels
531
HIV Stage III
* AIDS * most severe stage * opportunistic infections occur
532
WHO divides HIV progression into ___ clinical stages, which are based more on _____ \_\_\_\_\_.
* **4** clinical stages * based on clinical **manifestations**
533
risk factors for HIV
* unprotected sex * esp. receptive anal intercourse * ↑ rate of transmission w/ mucosal disruptions * multiple sex partners * exposure in workplace * fetal exposure * IV drug use, shared needles * blood transfusion before 1985 in U.S. * maternal HIV infection: birth, breastfeeding
534
MTCT
mother-to-child transmission
535
clinical manifestations of HIV
* subjective * flu-like Sx * chills and/or night sweats * malaise * anorexia, nausea * weakness * fatigue * HA * objective * rash: flat and red * fever * cough/SOB * wasting syndrome, wt loss * enlarged lymph nodes * poor wound healing * opportunistic infections
536
acute seroconversion
in HIV → flu-like illness: fever, malaise, rash
537
HIV sequelae
* AIDS-associated dementia/encephalopathy * wasting syndrome: chronic diarrhea and wt loss w/ no identifiable cause * fluid/electrolyte imbalance
538
opportunistic infections common in HIV patients
* fungal * TB * CMV * toxoplasmosis * herpes * HHV-8 * Epstein-Barr
539
HHV-8
* human herpesvirus 8 * → Kaposi's sarcoma in HIV pts
540
TB, CMV, toxoplasmosis and other opportunistic infections can lead to what problems in HIV pts?
adrenal dysfunction
541
Epstein-Barr virus is associated w/ what Dx in HIV pts?
Hodgkin's lymphoma
542
HIV-associated lipodystrophy syndrome
* side effect of protease inhibitor Tx * → * abnormal accumulations of body fat (upper back) * hypercholesterolemia * hyperglycemia/insulin resistence * hypertriglyceridemia
543
labs for HIV
* CBC * cell counts * CD4+ Th cells * CD8+ Ts cells * antigen/antibody * ELISA * Western blot assay * PCR * viral load * testing for other viruses
544
PCR for HIV
can detect HIV RNA in blood earlier than antigen/antibody tests
545
ELISA
* enzyme-linked immunosorbent assay * test for antibodies and antigens in blood
546
Western blot assay
* previously used to confirm HIV-positive ELISA * test for antibodies in blood
547
other infections routinely checked for in HIV pts
* PPD * CMV * other STDs * hepatitis A, B, and C
548
PPD
* purified protein derivative * TB skin test
549
diagnostics for HIV
* none * imaging based on S/Sx indicating co-infection
550
HAART
highly active antiretroviral therapy
551
highly active antiretroviral therapy (HAART)
* 3+ drugs working @ different stages of replication * 90% adherence required
552
HAART goals
* ↓ viral load * slow dz progression * prevent immune deterioration
553
Once HIV progresses to AIDS, survival is usually \< ___ yrs.
**2** yrs
554
mortality rate for untreated HIV
90%
555
average time from HIV infection to death
8-10 yrs
556
classes of anteretrovirals
* nucleoside reverse transcriptase inhibitors (NRTIs) * nonnucleoside reverse transcriptase inhibitors (NNRTIs) * protease inhibitors (PIs) * fusion inhibitors * entry inhibitors * CD4-directed post-attachment inhibitors * CCR5 co-receptor antagonists * HIV integrase strand transfer inhibitors
557
NRTI
* nucleoside reverse transcriptase inhibitor * antiretroviral
558
NNRTI
* nonnucleoside reverse transcriptase inhibitor * antiretroviral
559
PI
* protease inhibitor * antiretroviral
560
nucleoside reverse transcriptase inhibitors
antiretrovirals * abacavir * didanosine * emtricitabine * lamivudine * stavudine * tenofovir * zidovudine
561
nonnucleoside reverse transcriptase inhibitors
antiretrovirals * delavirdine * efavirenz * etravirine * nevirapine * rilpivirine
562
protease inhibitors
antiretrovirals * atazanavir * darunavir * fosamprenavir * indinavir * lopinavir/ritonavir * nelfinavir * saquinavir * tipranavir
563
fusion inhibitor
antiretroviral * enfuvirtide
564
CCR5 co-receptor antagonists
antiretrovirals, entry inhibitors * maravirac
565
CD4-directed post-attachment inhibitors
antiretrovirals, entry inhibitors * ibalizumab
566
WHO's 4 stages of HIV infection
* 1: asymptomatic * 2: mildly symptomatic * 3: moderately symptomatic * 4: severely symptomatic → AIDS
567
HIV pre-exposure prophylaxis (PrEP)
* antiretrovirals for prevention * for select, high-risk population * must be HIV– * labs * renal fxn * HIV * onset: 4 days' consistent dosing
568
PrEP
pre-exposure prophylaxis
569
PrEP can ↓ risk of HIV infection via sex by \_\_\_%.
**99**%
570
PrEP drugs
* PO daily * Truvada (emtricitabine/tenofovir disoproxil fumarate) * Descovy (emtricitabine/tenofovir alafenamide) * IM monthly: Cabenuva (cabotegravir/rilpivirine)
571
PrEP SEs
* diarrhea * nausea * HA * fatigue * stomach pain
572
nursing care for HIV
* **precautions** * **standard** * **immunocompromise** * monitor * wt * I&O * labs * assess * skin and provide care PRN * respiratory fxn
573
pt education for HIV
* importance of * medication adherence * follow-ups * infection control principles * support groups
574
Kaposi sarcoma
* KS * malignancy in lining of blood and lymph vessels * lesions: painless, purplish * etiology: HHV-8
575
KSHV
* Kaposi sarcoma-associated herpesvirus * HHV-8
576
Malignancies are named by _____ of \_\_\_\_\_.
**area** of **origin**
577
carcinoid tumor secretions
serotonin and other vasoactive substances
578
SPECT
* imaging technique * single photon emission computerized tomography
579
SOS
sinusoidal obstruction syndrome
580
veno-occlusive dz
* disruption in normal flow of venous blood from liver * complication of stem cell transplant, within 3 wks * S/Sx * hepatomegaly * RUQ pain * jaundice * ascites